User profiles for Maria Zambon
 | Professor Maria ZambonPublic Health England Verified email at phe.gov.uk Cited by 60581 |
Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
…, M Edmunds, M Zambon… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[HTML][HTML] Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
…, G Goderski, JL Romette, J Ellis, M Zambon… - …, 2020 - eurosurveillance.org
Background The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV)
poses a challenge for public health laboratories as virus isolates are unavailable while there …
poses a challenge for public health laboratories as virus isolates are unavailable while there …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
…, G Amirthalingam, M Edmunds, M Zambon… - The New England …, 2021 - ncbi.nlm.nih.gov
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective …
Background The SARS-CoV-2 delta (B.1.617.2) variant is highly transmissible and spreading
globally, including in populations with high vaccination rates. We aimed to investigate …
globally, including in populations with high vaccination rates. We aimed to investigate …
Duration of protection against mild and severe disease by Covid-19 vaccines
…, M Edmunds, M Zambon… - … England Journal of …, 2022 - Mass Medical Soc
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study …
Background Increased understanding of whether individuals who have recovered from
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to …
COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to …
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
Severe acute respiratory syndrome coronavirus 2 viral load in the upper respiratory tract
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group
…, GM Stephens, PCY Woo, AM Zaki, M Zambon… - Journal of …, 2013 - Am Soc Microbiol
During the summer of 2012, in Jeddah, Saudi Arabia, a hitherto unknown coronavirus (CoV)
was isolated from the sputum of a patient with acute pneumonia and renal failure (1, 2). The …
was isolated from the sputum of a patient with acute pneumonia and renal failure (1, 2). The …
